Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer
Gastroesophageal Cancer

Interventions: Drug: nivolumab
Drug: ipilimumab

First Posted Date: 2024-05-13

Last Posted Date: 2024-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT06410534

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

Phase 1

Not yet recruiting

Conditions: Very High Risk Prostate Carcinoma

Interventions: Radiation: [177Lu]Lu-PSMA-617
Drug: Ipilimumab

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: University Hospital, Essen

Target Recruit Count: 58

Registration Number: NCT06388369

Locations: 🇩🇪
University Hospital Essen, Clinic of Urology, Essen, Germany

CARE1 Pragmatic Clinical Trial

Phase 3

Recruiting

Conditions: Metastatic Kidney Cancer
Metastatic Kidney Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Pembrolizumab
Drug: Cabozantinib
Drug: Axitinib
Drug: Lenvatinib

First Posted Date: 2024-04-15

Last Posted Date: 2024-04-19

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 1250

Registration Number: NCT06364631

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Phase 2

Not yet recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2024-04-15

Last Posted Date: 2024-10-18

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 24

Registration Number: NCT06364917

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2024-04-15

Last Posted Date: 2024-12-11

Lead Sponsor: University of Utah

Target Recruit Count: 25

Registration Number: NCT06365619

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1

Recruiting

Conditions: Pleural Mesothelioma
Renal Cell Cancer
Kidney Cancer
Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
ALK Genomic Tumor Aberrations
Melanoma
Advanced Cancer
Metastasis
Advanced Solid Tumor
Skin Cancer

Interventions: Drug: Alintegimod
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2024-04-12

Last Posted Date: 2024-11-25

Lead Sponsor: 7 Hills Pharma, LLC

Target Recruit Count: 126

Registration Number: NCT06362369

Locations: 🇺🇸
Florida Cancer Specialists, Lake Mary, Florida, United States
🇺🇸
Dartmouth Hitchcock, Lebanon, New Hampshire, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Tiragolumab
Drug: Ipilimumab
Drug: Atezolizumab

First Posted Date: 2024-04-02

Last Posted Date: 2024-06-14

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 60

Registration Number: NCT06342037

Locations: 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands

Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1

Not yet recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC V8
Anatomic Stage IA Breast Cancer AJCC V8
Anatomic Stage IB Breast Cancer AJCC V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage IIB Breast Cancer AJCC V8
Anatomic Stage IIA Breast Cancer AJCC V8
Metastatic Triple-Negative Breast Carcinoma
Prognostic Stage IA Breast Cancer AJCC V8
Prognostic Stage IB Breast Cancer AJCC V8
Anatomic Stage III Breast Cancer AJCC V8

Interventions: Biological: Vaccine Therapy
Biological: Pembrolizumab
Biological: Ipilimumab

First Posted Date: 2024-03-21

Last Posted Date: 2024-11-05

Lead Sponsor: Emory University

Target Recruit Count: 18

Registration Number: NCT06324240

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 1 locations